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October 9, 2012:1430–7Medicinal Agency position in allowing both doses of dabigatran
etexilate studied in RE-LY (150 mg twice daily and 110 mg
twice daily), and also the U.S. Food and Drugs Administration
policy of recommending the even lower 75 mg twice daily dose
in selected conditions of poor renal function (1). Also for the
factor (F)Xa-inhibitors rivaroxaban and apixaban, a lower dose
has been used in the trials in selected conditions of poor renal
function and is recommended in the current or forthcoming
labels. In the phase III trial of the FXa inhibitor edoxaban in
nonvalvular atrial fibrillation, 2 exposure strategies and 3 dosing
regimens were tested to obtain a more personalized treatment
approach. Such trial design leads to the need for a very large
patient sample size in the pivotal phase III trial, which has not
always been possible because it is forbiddingly expensive. A
more feasible approach may be to test alternative dosing
regimens after regulatory approval, that is, in the context of
simple trials in a registry-like environment. This will allow a
firmer documentation of the best regimens and a considerably
more valid background than basing the choice of alternative
regimens only on pharmacokinetic considerations. Still, there is
no evidence that an individualized regimen with frequent
monitoring and dose changes is either safer or more effective
than a standard dose regimen, especially when using medica-
tions with a wider therapeutic window than vitamin K antag-
onists.
We very much warn against the proposal in the letter to extend
the clinical use of these new treatments to patients with mechanical
valves or hypercoagulable states based only on pharmacokinetic
considerations, other than in the design of real efficacy trials.
Patients with these diseases may well require drug dosing regimens
different from those evaluated so far in clinical trials. Specific
efficacy trials in these new settings are needed, and actually already
have begun.
We certainly agree with a plea for prudence in the use of these
new drugs, for which simplicity of use—undoubtedly much higher
than for vitamin K antagonists—may create the illusion of absence
of problems, which is certainly not the case.
*Raffaele De Caterina, MD, PhD
Steen Husted, MD, DSc
Lars Wallentin, MD, PhD
for the ESC Working Group on Thrombosis Task Force on
Anticoagulants in Heart Disease
*Institute of Cardiology
“G. d’Annunzio” University—Chieti
Ospedale SS. Annunziata
Via dei Vestini
66013 Chieti
Italy
E-mail: rdecater@unich.it
http://dx.doi.org/10.1016/j.jacc.2012.06.028
EFERENCE
1. De Caterina R, Husted S, Wallentin L, et al. New oral anticoagulants
in atrial fibrillation and acute coronary syndromes: ESC WorkingGroup on Thrombosis-Task Force on Anticoagulants in Heart Disease
Position Paper. J Am Coll Cardiol 2012;59:1413–25.
The Use of 18F-FDG-PET/CT
in the Diagnostic Workup
of CIED Infections:
Another Perspective
We read with great interest the article by Sarrazin et al. (1) on the
use of 18F-fluorodeoxyglucose (FDG)–positron emission tomog-
raphy (PET)/computed tomography (CT) in the diagnostic
workup of suspected cardiovascular implantable electronic device
(CIED) infections. This study indeed has great clinical potential.
In fact, as noted in the accompanying editorial (2), clinicians will
greatly benefit from a highly accurate diagnostic procedure to
confirm CIED infection, evaluate its extent, and guide the decision
whether to remove the device versus treating patients with antimi-
crobial treatment alone.
However, such an ambitious task will require more of a
problem-solving approach than a single test assessment. There-
fore, we believe that some comments may shed new light on the
findings of Sarrazin et al. (1). The authors indicated 88.6%
sensitivity and 85.7% specificity of 18F-FDG-PET/CT, the
latter increasing to 100% when a specific interpretation criterion
(abnormal/lung 18F-FDG uptake ratio 1.87) was applied.
Considering that the authors performed 18F-FDG-PET/CT in
patients with a high pre-test probability, the false positive rate
may be underestimated in this series. Therefore, such high
specificity is achievable by adopting accurate patient selection
and inclusion criteria. Indeed, the application of 18F-FDG-
PET/CT in patients with lower pre-test probability will rely on
the high negative predictive value of the technique. In fact, up
to 8% of false-positive findings has been reported in patients
with pacing systems without signs of infection (3). For lower-
risk patients, higher-specificity techniques such as 99mTc–
hexamethylpropyleneamine oxime–leukocyte single-photon
emission CT (SPECT)/CT, as recently reported for infective
endocarditis (4), might be considered. In this regard, the
general notion of the lower spatial resolution for SPECT/CT
compared with PET/CT should consider improvements achiev-
able with current-generation hybrid SPECT/spiral CT scanner
(5,6). Finally, specific information about the type of microor-
ganisms and data on concomitant antimicrobial treatment,
particularly on the type of agents and their activity on biofilm
formation (7), will help in the understanding of false-negative
rates (4 cases in this paper) and therefore estimation of
limitations of the test. For example, as also mentioned in the
editorial, microorganisms such as Enterococcus and Candida have
the ability to elude leukocyte recruitment (8,9), possibly affect-
ing PET/CT results. Additionally, because this paper stated
that 42% of patients with limited superficial skin infections at
PET scan were treated with antimicrobial agents only, a higher
rate as compared with the recommendation for CIED removal
(10), the evaluation of microbiological results in this subgroup
is critical. Considering the low rate of negative CIED pocket
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October 9, 2012:1430–7cultures (14%) reported in the literature (11), either a bias in
atient recruitment or in the selection of follow-up duration
hould also be taken into account. Therefore, microbiological,
chocardiographic, and treatment information is essential to
larify the reason for the false-negative cases at 18F-FDG-PET/
CT, particularly for high pre-test likelihood. None of the
diagnostic techniques available represent by themselves the
“magic” tool: the application of patients’ tailored strategies
starting from the multidisciplinary comprehensive interpreta-
tion of clinical history and complete clinical characterization to
identify the most suitable diagnostic test rather then the use of
the single best test will be the strategy to increase the diagnostic
accuracy, therefore impacting patients’ management.
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ositron Emission Tomography
nd Computed Tomography in
atients With Suspected
ardiovascular Implantable
lectronic Device Infection
Sarrazin et al. (1) highlighted the usefulness of positron emission
tomography (PET)/computed tomography (CT) in patients with
suspected cardiovascular implantable electronic device infection
(CIED). The following points should be considered before reach-
ing a final conclusion.
1. Guidelines recommend avoiding fluorodeoxyglucose (FDG)-
PET scans when blood glucose level is 200 mg% in patients
with cancer because hyperglycemia compromises the diagnostic
ability by decreasing FDG uptake (2,3). Did the authors make
an attempt to study the impact of hyperglycemia on the
sensitivity and specificity of the scan because hyperglycemia is
common in patients with CIED infection?
2. In the study by Sarrazin et al. (1), how many patients received
antibiotic therapy before the scan and for how long of a
duration? What was the impact of prior antibiotic therapy on
the sensitivity and specificity of the scan?
3. Increased FDG uptake is nonspecific and may be increased in
the setting of inflammation, infection, malignancy, or clot
formation, whereas it may be decreased in patients with
leukopenia even in the presence of infection (4,5).
4. What is the impact of the scan results on patient management?
This question remains unanswered because the decision to treat
was not based on scan findings. Larger-scale prospective studies
with longer follow-up periods (to rule out any latent infection)
are required before supporting a conservative approach for
negative scans in patients with bacteremia.
Considering high scan cost, FDG-PET/CT should only be
used as an adjunct diagnostic test in selective patients with CIED
in whom routine workup of fever (including transesophageal
echocardiography) remains inconclusive.
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